Acadia Healthcare enters Tuesday's Q2 earnings call with one of the more interesting short-positioning stories in healthcare services: a heavy bear presence that has been unwinding fast, against a backdrop of analyst upgrades and a stock that has more than recovered from its April lows.
Short interest remains elevated at 22.7% of the free float — still in the top tier of the healthcare universe — but the direction has shifted sharply. Bears cut positions by roughly 9.3% over the past week and by 15.8% over the past month, bringing outstanding short shares down from a mid-July peak near 24 million to just under 21 million. The borrow market reinforces the picture of a less aggressive short base: availability has expanded to 136% of short interest, up 22% on the week, meaning there is ample stock available to borrow for anyone who wants to initiate or add to a short. Cost to borrow is barely above 0.5% — essentially zero friction. Shorts are not being squeezed out; they appear to be leaving voluntarily. The ORTEX short score, running at 72, still flags elevated short conviction, but it has eased from a week-ago reading near 74. Options traders, meanwhile, are neither hedging aggressively nor chasing calls: the put/call ratio at 0.57 is fractionally below its 20-day average of 0.59, essentially neutral. That combination — shorts reducing exposure, borrow staying loose, options flat — suggests the market is in wait-and-see mode rather than making a directional bet ahead of the release.
The bull case rests on the recovery thesis. Analysts have been raising targets in a tight cluster over the past two weeks, with UBS, TD Cowen, KeyBanc and Guggenheim all lifting price targets — several by $8-9 — while maintaining positive ratings. The consensus view is that Q1's headwinds around payor denials and facility closures were isolated rather than structural, and that management's operational response is gaining traction. KeyBanc carries the most aggressive target at $40, implying meaningful upside from the current $32.69 close. The bear case, however, has not fully gone away: Barclays holds at Equal-Weight with a $25 target, and the stock's 19% one-month rally leaves valuation less comfortable — the forward PE has expanded to roughly 19.7x, up nearly 3 points over the past month. EPS surprise history is a genuine concern for bulls too: the factor score ranks in just the 16th percentile, meaning Acadia has not been a reliable beat-and-raise story. After April's print, the stock fell more than 6% on the day and extended losses to 13% over the following five days.
The institutional register adds a layer of interest. BlackRock added roughly 2.4 million shares through June 30, lifting its stake to 12.7% of shares outstanding — the largest position in the book. Fidelity (FMR) added 1.4 million shares in the same window. Both moves represent fresh conviction ahead of an earnings season that the stock's April reaction suggests can be brutal on disappointment. Greenlight Capital and Khrom Capital are also on the register, the former adding modestly and the latter trimming by nearly 2 million shares through March — a divergence that mirrors the broader bull-bear debate around whether Acadia's operational fixes are real or still in progress.
Tuesday's print is therefore a test of whether the denial and bad-debt narrative management has labelled "isolated" shows up in the numbers, or whether Q2 marks the quarter where guidance finally reflects the cleaner operational trajectory that bulls — and now several sell-side desks — have been buying into.
See the live data behind this article on ORTEX.
Open ACHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
